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Abstract: Bacillus anthracis, similar to other bacterial pathogens, has evolved effective 
immune evasion strategies to prolong its survival in the host, thus ensuring the unchecked 
spread of the infection. This function is subserved by lethal (LT) and edema (ET) toxins, 
two exotoxins produced by vegetative anthrax bacilli following germination of the spores. 
The structure of these toxins and the mechanism of cell intoxication are topics covered by 
other reviews in this issue. Here we shall discuss how B. anthracis uses LT and ET to 
suppress the immune defenses of the host, focusing on T lymphocytes, the key players in 
adaptive immunity. We shall also summarize recent findings showing that, depending on 
its  concentration, ET has  the ability not  only to suppress  T  cell activation but  also to 
promote the polarization of CD4
+ T cells to the Th2 and Th17 subsets, highlighting the 
potential use of this toxin as an immunomodulator. 
Keywords: lethal  toxin; edema toxin;  T cell;  Th subset;  TCR signaling;  cAMP;  MAP 
kinases; immunosuppression; immunodeviating 
 
1. Introduction 
Bacteria have developed a variety of strategies to hamper or modify the host immune response to 
establish a productive infection. Bacillus anthracis has a challenging interaction with the host in that it 
exploits macrophages, the first line of defense of the innate immunity, to reach the heart of the immune 
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system, the lymph node. B. anthracis invades the host through one of three known portals—upper 
airways, gastrointestinal tract or skin—in the form of metabolically inert spores which must germinate 
to become pathogenic bacilli. This crucial function is subserved by phagocytes patrolling the tissues, 
such as alveolar macrophages or lung dendritic cells (DC) in inhalational anthrax. Following their 
ingestion by the phagocytes, the spores are carried through the lymphatics to the regional lymph nodes, 
where they germinate to become vegetative bacilli that are first released locally and eventually enter 
the bloodstream [1].  
Pathogenic strains of B. anthracis produce a deadly tripartite toxin, which is composed of protective 
antigen (PA), lethal factor (LF) and edema factor (EF) [2]. The three toxin components combine to 
form  two  binary  toxins,  the  lethal  toxin  (LF+PA)  and  the  edema  toxin  (EF+PA),  that  help  the 
bacterium to evade the immune system and eventually kill the host if the infection becomes systemic. 
PA consists of four domains, of which the C-terminal domain is released upon proteolytic cleavage by 
a furin-like membrane protease or by a serum protease, resulting in oligomerization of truncated PA 
into  heptamers  or  octamers  that  bind  EF  and  LF.  The  PA-EF  or  the  PA-LF  complexes  are  then 
endocytosed inside acid compartments. The low pH of the endosomal lumen induces a conformational 
change of the complex which results in the insertion of PA into the lipid bilayer and translocation of 
LF and EF to the cytosol [3]. LF is a zinc metalloprotease which cleaves and inactivates several 
members of the MAPKK family [4–6]. EF is a Ca
2+/calmodulin dependent adenylate cyclase which 
produces  large  amounts  of  the  second  messenger  cAMP  [7,8].  By  interfering  with  the  signaling 
pathways  activated by a variety of surface receptors the anthrax toxins dismantle the first line of 
defense  of  the  immune  system  [1,9].  LT  and  ET  blunt  in  fact  the  production  and  release  of 
proinflammatory  mediators  by  macrophages  and  promote  their  apoptosis,  thus  preventing 
polymorphonuclear  cell  recruitment  to  the  site  of  infection  and  pathogen  clearance  [1,9–12]. 
Furthermore  both  toxins  impair  DC  activation  and  maturation,  thus  preventing  the  initiation  of 
adaptative immunity [13].  
While the impairment of DC functions could efficiently prevent per se mounting of the adaptive 
immune  response,  B.  anthracis  also  directly  targets  the  central  regulators  of  adaptive  immunity,  
i.e., B and T lymphocytes. LT dramatically reduces B cell proliferation and impairs immunoglobulin 
production [14]. Moreover by targeting T lymphocytes, which are the specific subject of this review,  
B. anthracis ensures a complete coverage of all the actors responsible for the immune defenses of the host.  
2. T Cells as Targets of the Anthrax Toxins 
Although spore germination, and hence toxin production, is believed to occur in the regional lymph 
nodes, a recent report has challenged this view. Using in vivo imaging of infected mice, Glomski et al. 
have  provided  evidence  that  the  spores  germinate  and  establish  initial  infections  at  the  site  of 
inoculation in both inhalational and gastrointestinal infections, in nasal-associated lymphoid tissues 
and Peyer’s patches, respectively, without needing to be transported to the draining lymph nodes [15]. 
While the concentrations of LT and ET have been measured to date only in the blood during systemic 
infection [16], this important finding suggests that the anthrax toxins can accumulate locally to levels 
sufficiently high to interfere with the function not only of the resident phagocytes, but also of the 
immune cells present in the mucosa associated lymphoid tissue, including T cells.  Toxins 2011, 3                                       
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The  identification  of  the  anthrax  toxin  receptors  (ANTXR1  and  ANTXR2)  [17–19]  provided 
support to the notion that not only are T cells suitably located to be targeted by the toxins, but also 
have the means to become effectively intoxicated. T cells express indeed both TEM8 (ANTXR1) and 
CMG2  (ANTXR2),  the  latter  being  the  prevalent  form,  at  least  in  mouse  splenic  CD4
+  and  
CD8
+ T cells [18,20]. After their delivery to the cytosol, the catalytic subunits of LT and ET have the 
potential  to  subvert  the  signaling  pathways  that  control  the  activation  of  naï ve  T  cells  and  their 
subsequent  differentiation  to  armed  effectors  by  interfering  with  the  MAPK  and  cAMP/PKA 
dependent signaling cascades, which are centrally implicated in these processes [21,22].  
3. LT and ET Suppress T Cell Activation 
Both LT and ET potently suppress human T lymphocyte activation in vitro, as assessed by surface 
expression of activation markers (CD69, CD25), cytokine secretion (IL-2, TNF-α, IFN-ʳ, IL-5) and 
proliferation [23,24]. This direct inhibitory activity on CD4
+ T cells has been also reported in the 
mouse, where the toxins have been shown to impair T cell antigen receptor (TCR) mediated T cell 
activation, cytokine production (IL-3, IL-4, IL-5, IL-6, IL-10, IL-17, GM-CSF, TNF-α, IFN-ʳ) and 
proliferation  both  in  vitro  and  ex  vivo  after  administration  of  sublethal  doses  of  LT  or  ET  [25].  
A similar effect has recently been observed on CD1d-restricted NKT cells, which play an important 
role in the orchestration of a protective adaptive response against pathogens [26]. Of note, LT and ET 
synergize in suppressing T cell activation at concentrations which alone elicit minor effects [23]. This 
is likely to be of relevance at the onset of infection, when the local toxin concentrations may be too 
low to effectively target the immune cells. It should be emphasized that immunological memory in 
survivors of bioterrorism related inhalational anthrax (measured as anti-PA antibody titers) [27], as 
well as CD4
+ T cell responses in individuals previously naturally infected with cutaneous anthrax [28], 
are  functional  several  months  or  years  after  successful  antibiotic  treatment  of  the  infection.  This 
indicates that the impairment in adaptive immunity observed following T cell treatment with LT or ET 
in vitro, or short-term in vivo administration of the toxins to mice, is not long-lasting and may be 
instrumental only at the onset of infection to ensure survival of the vegetative bacilli until colonization.  
Inihibition of T cell activation by LT and ET is dependent on the respective enzymatic activities. 
Commitment to T cell activation is characterized by the temporally regulated expression of a subset of 
genes, which eventually leads to the proliferation of antigen specific T cells and acquisition of effector 
functions.  Both  the  classical  MAPK  cascade,  whose  endpoint  is  Erk  [22],  and  the  stress  kinase 
cascades, whose endpoints are p38 and JNK [29], are implicated in coupling the TCR to this complex 
gene expression cascade. LT and ET have both the potential to disable these pathways. LT can do so 
directly by cleaving MAPKKs, while the effect of ET is mediated by molecular targets of its cAMP 
elevating activity. Among these, PKA has a prominent role. By producing cAMP, ET activates PKA, 
which  impairs  Ras  activation  indirectly  by  activating  the  Ras  antagonist,  Rap1,  and  moreover 
inactivates the first MAPK in the cascade, Raf, by phosphorylating an inhibitory serine residue. PKA 
impairs moreover the activation of the stress kinases by blocking the activation of the small GTPase 
Rho [30] (Figure 1). Hence MAPKs represent a point of convergence of the intracellular activity of the 
two anthrax toxins. Interestingly, after release to the cytosol from late ensodomes, ET remains bound 
to the these organelles [31], thereby generating high levels of cAMP compartmentalized close to this Toxins 2011, 3                                       
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location,  which  results  in  the  induction  of  waves  of  activated  PKA  emanating  from  perinuclear  
foci [32]. This suggests that not only is PKA activated to abnormally high and sustained levels in the 
presence of ET, but that pools of PKA which are normally not implicated in the control of TCR 
signaling may be mobilized under these conditions.  
It must be emphasized that ET has the potential not only to impair the MAPK cascades, but also to 
antagonize TCR signaling beginning from the earliest steps. Initiation of TCR signaling is crucially 
dependent on phosphorylation of the intracellular tails of the the CD3 complex subunits by the tyrosine 
kinase Lck. This results in the generation of docking sites for the second tyrosine kinase in the cascade, 
ZAP-70 which, when bound to CD3ʶ, becomes activated and in turn phosphorylates a number of key 
substrates. Among these is the transmembrane adaptor LAT, which forms a scaffold for the assembly 
of a multimolecular signaling complex that couples the TCR to downstream events [33]. The activity 
of  Lck  is  negatively  regulated  by  the  kinase  Csk,  which  is  potentiated  by  PKA  (Figure  1).  By 
promoting  the  activation  of  PKA  through  its  cAMP  elevating  activity  ET  may  contribute  to 
maintaining Lck in an inactive state, thereby preventing firing of the TCR signaling cascade. This has 
been  found  to  be  indeed  the  case.  ET  prevented  TCR  mediated  Lck  activation  and  CD3ʶ 
phosphorylation in human peripheral T cells, which resulted in a generalized defect in downstream 
signaling  [34].  This  implies  that  ET  has  not  only  the  potential  to  specifically  target  the  MAPK 
cascades, but can cripple TCR signaling as a whole. 
Figure 1. Effects of the anthrax toxins on T cell activation. Lethal (LT) and edema (ET) 
block T cell activation and proliferation by interfering with T cell antigen receptor (TCR) 
signaling. LT does so directly by cleaving MAPKKs, while the effect of ET is mediated by 
molecular targets of its cAMP elevating activity.  
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4. LT and ET Impair T Cell Chemotaxis 
Orchestration of the immune response is crucially dependent on immune cell migration and homing, 
which is finely tuned by chemokines [35]. Naï ve T lymphocytes recirculate continuously from the 
bloodstream  to  lymphoid  organs.  There  they  sample  APCs  which  have  migrated  from  the  site  of 
infection after uptake of the pathogen or its secreted products. T cells that have encountered an APC 
bearing MHC bound cognate antigen stop, become activated, proliferate and differentiate to armed 
effectors. Effector T cells then exit the lymphoid organs and patrol the body in search of the site where 
the invading pathogen is located. In response to certain chemokines, T cells migrate to the inflamed 
tissue and cooperate with the phagocytes to clear the infection [36].  
Chemotaxis  is  orchestrated  by  chemokine  receptors,  which  are  seven  spanning  transmembrane 
receptors coupled to heterotrimeric Gi proteins that modulate the activity of adenylate cyclases. These 
receptors activate MAPKs through their inhibitory activity on cAMP production. Furthermore, they 
initiate  a  tyrosine  kinase  dependent  pathway  leading  to  the  activation  of  MAPKs  [35].  Pathways 
initiated by chemokine receptors are therefore potential targets of the two anthrax toxins. LT and ET 
have indeed been found to block T cell chemotaxis [37] (Figure 2). This inhibition correlates with 
suppression of MAPK activation in response to the chemokines. Interestingly, both toxins also inhibit 
macrophage  chemotaxis  [37].  Hence,  by  inhibiting  migration  of  both  APC  and  T  cells  through 
disruption of MAPK signaling, B. anthracis can prevent the initiation of adaptive immune responses 
upstream of antigen presentation. Furthermore, it can suppress recruitment of phagocytes and effector 
cells to the site of infection. This is likely to be very relevant to cutaneous anthrax, where impaired 
chemotaxis might account for the observed delay in bacterial clearance and wound healing [38]. 
Figure 2. Effects of the anthrax toxins on T cell chemotaxis. LT and ET inhibit T cell 
chemotaxis by disrupting the MAP kinase dependent pathways orchestrated by chemokine 
receptors which control the dynamics of the actin cytoskeleton. 
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5. Immunodeviating Activity of ET on CD4
+ T Cells 
Dependent on the environment to which they are exposed upon encounter with antigen presented by 
APCs, naï ve CD4
+ T cells enter a complex differentiation program which leads to the development of 
at least three effector subsets with distinct and complementary properties, known as Th1, Th2 and 
Th17.  Th1  cells  are  generally  responsible  for  cell-mediated  immunity,  enhancing  the  function  of 
macrophages  by  producing  pro-inflammatory  cytokines.  Th17  cells  are  a  recently  described 
proinflammatory subset that complements the function of Th1 cells by promoting the recruitment and 
activation of phagocytes. The Th2 subset is mainly responsible for optimizing the humoral response by 
promoting  the  maturation  of  activated  B  cells  to  antibody-producing  plasma  cells  [39–41].  While  
Th  subsets  have  evolved  to  coordinate  the  adaptive  response  to  pathogens,  an  alteration  in  their 
balance can result in immune related pathological outcomes. The link between Th2 cells and bronchial 
asthma, or the association of Th1 and Th17 with autoimmune diseases, are striking examples of the 
consequences of an aberrant bias towards a specific Th subset [39]. As such, Th subsets are relevant 
targets both in the treatment of various immune related diseases and in vaccination.  
Helper T cell subsets can be identified based on unique cytokine profiles, which are dictated by 
master transcription factors. These highly specific developmental programs are set during priming by 
the APC, which provides not only MHC bound antigen, but also developmental cues in the form of 
cytokines or lipid mediators. The latters include PGE2, which depending on the context can either 
suppress  T  cell activation or promote their differentiation and/or  expansion to  the Th2 subset, an 
activity which has recently been extended to the Th17 subset [42–47]. This results from the ability of 
the PGE2 receptors to induce cAMP accumulation and PKA activation. Although the cytokines driving 
the differentiation of the three subsets are known, very little is known about how the TCR signaling 
cascade is modulated to result in developmental outcomes so profoundly different. Nevertheless, PKA 
has been implicated as a negative regulator of Th1 cell development and, together with the kinase 
PDK1, as a positive regulator of Th2 cell development [48].  
When co-administered with antigen at low concentrations in the mouse, ET has been shown to act 
as an adjuvant, enhancing the humoral response by promoting the generation of antigen specific Th2 
cells.  Although  this  results,  at  least  in  part,  from  the  modulation  of  cytokine  production  by  
APCs [49,50], we have recently reported that  ET can directly promote the polarization  of human  
CD4
+ T cells to Th2 cells in the absence of APC [34]. These experiments were carried out using a 
concentration of ET that was not immunosuppressive but was able to elicit a modest accumulation of 
cAMP  and  activate  PKA.  When  peripheral  T  cells  treated  with  this  low  ET  concentration  were 
activated by TCR ligation in the absence of any cytokine, they polarized towards the Th2 lineage, as 
assessed by their cytokine profile and expression of the Th2 trascription factors, c-maf and GATA-3. 
As expected from the known Th1/Th2 cross-inhibition [39–41], Th1 development was impaired. We 
have recently shown that ET also promotes the robust polarization of CD4
+ T cells to the Th17 subset, 
as shown by the pattern of cytokines (IL-23, IL-21, IL-22), cytokine receptors (IL-1R, IL-23R) and 
transcription factors (RORʳ) [51] (Figure 3). Consistent with the Th2 and Th17 polarizing activity of 
PGE2, these effects were not reproduced by a catalytically inactive ET mutant, indicating that they are 
mediated by the cAMP elevating activity of the toxin.  Toxins 2011, 3                                       
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Figure  3.  Effects  of  ET  on  helper  T  cell  polarization.  ET  promotes  CD4
+  T  cell 
polarization  to  Th2  and  Th17  effectors  by  modulating  TCR  signaling  to  promote  the 
expression  of  the  transcription  factors  c-Maf/GATA-3  and  RORʳ,  which  are  in  turn 
responsible for the expression of the Th2 driving cytokines IL-4 and IL-13, and the Th17 
driving cytokines IL-17, IL-21 and IL-22, respectively. 
 
Remarkably,  early  TCR  signaling  was  not  impaired  in  the  presence  of  the  immunodeviating 
concentration  of  ET,  as  assessed  by  CD3ʶ  phosphorylation  and  ZAP-70  activation.  However  the 
activation  of  individual  signaling  mediators  implicated  in  Th1  and  Th2  cell  development  was 
substantially  affected  by  ET  [34].  Specifically,  TCR  dependent  phosphorylation  of  Akt,  a  kinase 
implicated in Th1 cell development and negatively regulated by PKA [48], was found to be impaired 
in the presence of ET. Conversely, activation of Vav, a guanine nucleotide exchanger responsible for 
the activation of Rho family GTPases and known to be required for Th2 cell development [52], as well 
as  the  downstream  stress  kinase  p38,  were  found  to  be  enhanced.  Hence  ET  favors  Th2  cell 
development by shaping TCR signaling to selectively modulate the activation of individual specific 
signaling mediators without an overall modification of the signaling cascade. How ET modulates TCR 
signaling to promote the polarization of Th17 cells, as well the mechanisms underlying the mixed 
Th2/Th17 polarizing activity of ET (and PGE2), remain to be defined.  
To date the potential immunomodulatory activity of LT on helper T cell polarization has not been 
addressed. Nevertheless, both the MAP and the stress kinases have been implicated in CD4
+ T cell 
lineage commitment, suggesting that LT might also affect this process.  Toxins 2011, 3                                       
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The Th2 driving activity of ET is likely be relevant to cutaneous anthrax, where there is a limited 
toxin  production  and  where  resolution  of  infection  has  been  correlated  to  the  development  of  an 
antibody response against the toxins. On a more general note, both Th2 and Th17 cells are involved in 
the development of effective vaccine induced memory responses against infectious diseases [49]. An 
important implication of the Th2/Th17 immunodeviating activity of ET, which can be reproduced by 
the  unrelated  adenylate  cyclase  toxin  of  Bordetella  pertussis,  CyaA  [34,51],  is  that  cAMP  might 
enhance  the  efficacy  of  vaccines  by  acting  on  both  the  humoral  and  cellular  arms  of  adaptive 
immunity. In fact, the dual Th2/Th17 polarizing activity of ET could account for the robust humoral 
and cell-mediated immunity in survivors of anthrax infections [53]. 
6. Conclusions  
Although upon infection bacterial pathogens are immediately confronted by the first line defenses 
provided by the innate immune system, they eventually have to deal with the highly specific and 
powerful  adaptive  defenses.  Hence  the  systematic  disabling  of  the  innate  and  adaptive  immune 
defenses  appears  as  an  effective  survival  strategy  evolved  by  B.  anthracis  to  achieve  successful 
colonization, particularly in the more common disease presentation, i.e., cutaneous anthrax. For this 
crucial task the bacterium uses two toxins which target signaling mediators that are among the most 
conserved in eukaryotic cells, from yeast to mammals. The importance of these targets is witnessed by 
the fact that unrelated pathogens have evolved similar or different mechanisms to ultimately inactivate 
or subvert their function, as strikingly exemplified by the widespread usage of adenylate cyclases or 
cAMP modulating toxins as virulence factors [54]. As, such, these toxins provide a unique tool not 
only to understand the interaction of the pathogen with the host, but to achieve insight into the cellular 
processes regulated by the toxin targets. For example, cAMP/PKA signaling is crucially implicated in 
the modulation of TCR signaling, acting in both positive and negative regulatory networks that are 
subject to a tight spatiotemporal control and which, when subverted, can lead to unwanted oucomes, 
such  as  T  cell  anergy  or  apoptosis  [21].  The  underlying  mechanisms  are  finally  beginning  to  be 
unraveled. As summarized here for B. anthracis ET and as reported for B. pertussis CyaA [34,51,55], 
bacterial adenyate cyclase toxins have opened a unique point of observation to elucidate this important 
biological question.  
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